Samarium Sm-153

DB12905InvestigationalSmall molecule

Samarium Sm-153 is a radiopharmaceutical indicated in the treatment of bone pain in patients with skeletal metastases. Samarium 153 has been used in trials studying the supportive care of Pain, Lung Cancer, Breast Cancer, Prostate Cancer, and Metastatic Cancer.

Chemical structure of Samarium Sm-153
Mechanism
Curator reviewed
Formula / weight
Sm · 152.9221 g/mol (avg)
Also known as
153SM · Samarium 153 · Samarium Sm153 · Samarium-153 · SM-153

Resolves to

Compound
UNII6Q1KA41UWMCAS15766-00-4PubChem114941
Clinical / RWD
RxNorm196342
Structure
InChIKeyKZUNJOHGWZRPMI-AKLPVKDBSA-NSMILES[153Sm]
Targets
P06731CEACAM5

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
7ContraindicationsEach with its own population and attribute set
Sign in
1Marketed productAcross 1 country and 1 labeller
Sign in
2+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Samarium Sm-153, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In